{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
lactic acid
to a specific field?
Status:
Investigational
Source:
NCT03313297: Phase 2 Interventional Completed Diabetes Mellitus, Type 2
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
AZD4017, a 11β-hydroxysteroid dehydrogenase type 1 inhibitor, has been developed by AstraZeneca for the treatment of obesity, raised intraocular pressure (IOP) and type 2 diabetes. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. However, studies were discontinued due to safety and efficacy reasons. Besides, specific inhibition of 11β-HSD1 can decrease intracranial pressure and consequently treat patients with Idiopathic Intracranial Hypertension (IIH), thus AZD4017 participated in phase II clinical trials to treat this disease. IIH, also known as benign intracranial hypertension or pseudotumor cerebri, is a condition of unknown etiology characterized by elevated intracranial pressure (ICP) and papilledema. In addition, AZD4017 in combination with prednisolone participated in phase II clinical trials for patients with Iatrogenic Cushing's Disease. It was postulated that the adverse metabolic effects of prednisolone could be reduced by co-administration of AZD4017.
Status:
Investigational
Source:
NCT01954615: Phase 1 Interventional Completed Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
ACT-281959 (molecular weight 850.9 g/mol), the di-ester prodrug of
ACT-246475 (molecular weight 618.6 g/mol), was developed to improve absorption after oral dosing and is rapidly converted by esterases in vivo to ACT-246475 in two-steps via the formation of ACT-409100 (molecular weight 734.7 g/mol), the mono-ester prodrug. ACT-281959 is a novel potent and selective P2Y12 receptor antagonist with a wider therapeutic window. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers. ACT-281959 had been in phase I clinical trials by Actelion for the treatment of thrombosis. But there is no development reported for this study recently.
Status:
Investigational
Source:
NCT02800590: Phase 2 Interventional Completed Colonoscopy
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MDCO 700 (formerly ABP 700) is hypnosedative and anaesthetic agent that was being developed by The Medicines Company for the induction of general anesthesia and procedural sedation. It is a positive allosteric modulator of the GABAA receptor. It is a second generation analogue of etomidate, developed to retain etomidate's beneficial haemodynamic and respiratory profile but diminishing its suppression of the adrenocortical axis. Infusions of ABP-700 showed a dose-dependent hypnotic effect, and did not cause severe hypotension, severe respiratory depression, or adrenocortical suppression. The drug development for anaesthesia has been discontinued.
Status:
Investigational
Source:
NCT03175354: Phase 2 Interventional Completed Atopic Dermatitis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02106338: Phase 1 Interventional Completed Clostridium Difficile Infection
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
CRS-3123, also known as REP-3123, is a methionyl-tRNA synthetase inhibitor potentially for the treatment of enteric infections. CRS-3123 is in Phase 1 clinical development for the treatment of Clostridium difficile Infection (CDI). CRS-3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). REP-3123 has been shown to be active in vitro against clinical
isolates of C. difficile including epidemic strains such as B1/
NAP1/027; MIC values of REP-3123 for C. difficile are
typically 0.5 -- 1.0 mg/l. REP-3123 is also active against a range of clinically important aerobic Gram-positive bacteria
including methicillin-susceptible and -resistant Staphylococcus
aureus (MIC90 values of 0.06 and 0.25 mg/l, respectively),
Streptococcus pyogenes (MIC90 0.5 mg/l) and enterococci
(MIC90 32 mg/l). CRS-3123 has numerous potential advantages over current CDI therapies. In addition to being highly potent against all clinical isolates of C. difficile tested, CRS-3123 has several desirable qualities for the treatment of CDI which include:
Narrow spectrum for C. difficile, which may substantially reduce the disruption of normal intestinal flora compared to current therapies;
Inhibition of toxin production, potentially leading to lower morbidity and mortality;
Inhibition of sporulation, potentially leading to lower rates of transmission and recurrence;
A novel mechanism of action, which means that its use will not compromise the utility of systemic antibiotics while maintaining activity against pre-existing resistance mechanisms.
Status:
Investigational
Source:
NCT04701216: Phase 1 Interventional Completed Healthy Volunteers
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01038440: Not Applicable Interventional Completed Sudden Cardiac Death
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00942656: Not Applicable Interventional Completed Cardiovascular Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Vaccenic acid (VA) (t11 octadecenoic acid) is a positional and geometric isomer of oleic acid (c9-octadecenoic acid), and is the predominant trans monoene in ruminant fats (50%–80% of total trans content). Dietary VA can be desaturated to cis-9,trans-11 conjugated
linoleic acid (c9,t11-CLA) in ruminants, rodents,
and humans. Hydrogenated plant oils are another source of VA in
the diet, and it has been recently estimated that this source
may contribute to about 13%–17% of total VA intake. In contrast to suggestions from the epidemiological studies,
the majority of studies using cancer cell lines (Awad et
al. 1995; Miller et al. 2003) or rodent tumors (Banni et al.
2001; Corl et al. 2003; Ip et al. 1999; Sauer et al. 2004)
have demonstrated that VA reduces cell growth and (or) tumor
metabolism. Animal and in vitro studies suggest that
the anti-cancer properties of VA are due, in part, to the in
vivo conversion of VA to c9,t11-CLA. However, several additional
mechanisms for the anti-cancer effects of VA have
been proposed, including changes in phosphatidylinositol
hydrolysis, reduced proliferation, increased apoptosis, and inhibition
of fatty acid uptake. In conclusion,
although the epidemiological evidence of VA intake
and cancer risk suggests a positive relationship, this is not
supported by the few animal studies that have been performed. The majority of the studies suggest that any health benefit
of VA may be conferred by in vivo mammalian conversion
of VA to c9,t11-CLA. VA acts as a partial agonist to both peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ in vitro, with similar affinity compared to commonly known PPAR agonists. Hypolipidemic and
antihypertrophic bioactivity of VA is potentially mediated
via PPAR-/-dependent pathways.
Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02898779: Phase 1 Interventional Completed Malaria
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
